vs

Side-by-side financial comparison of Direct Digital Holdings, Inc. (DRCT) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.

Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $8.4M, roughly 1.6× Direct Digital Holdings, Inc.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs -138.7%, a 214.4% gap on every dollar of revenue.

Devolver Digital, Inc. is an American video game publisher based in Austin, Texas, specializing in the publishing of indie games. The company was founded in June 2009 by Nigel Lowrie, Harry Miller, Graeme Struthers, Rick Stults, and Mike Wilson, five executives who had been involved with Gathering of Developers and Gamecock Media Group, which published games on developer-friendly terms, but due to the high cost associated with releasing retail games saw themselves acquired and dissolved by la...

Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.

DRCT vs XLO — Head-to-Head

Bigger by revenue
XLO
XLO
1.6× larger
XLO
$13.7M
$8.4M
DRCT
Higher net margin
XLO
XLO
214.4% more per $
XLO
75.7%
-138.7%
DRCT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DRCT
DRCT
XLO
XLO
Revenue
$8.4M
$13.7M
Net Profit
$-11.7M
$10.4M
Gross Margin
26.8%
Operating Margin
-53.4%
-86.5%
Net Margin
-138.7%
75.7%
Revenue YoY
-7.4%
Net Profit YoY
-434.7%
179.1%
EPS (diluted)
$-74.97
$-3.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DRCT
DRCT
XLO
XLO
Q4 25
$8.4M
$13.7M
Q3 25
$8.0M
$19.1M
Q2 25
$10.1M
$8.1M
Q1 25
$8.2M
$2.9M
Q4 24
$9.1M
Q3 24
$9.1M
Q2 24
$21.9M
Q1 24
$22.3M
Net Profit
DRCT
DRCT
XLO
XLO
Q4 25
$-11.7M
$10.4M
Q3 25
$-2.7M
$-16.3M
Q2 25
$-2.2M
$-15.8M
Q1 25
$-2.4M
$-13.3M
Q4 24
$-2.2M
Q3 24
$-2.7M
Q2 24
$-590.0K
Q1 24
$-775.0K
Gross Margin
DRCT
DRCT
XLO
XLO
Q4 25
26.8%
Q3 25
27.7%
Q2 25
35.1%
Q1 25
29.3%
Q4 24
32.5%
Q3 24
38.7%
Q2 24
27.1%
Q1 24
22.4%
Operating Margin
DRCT
DRCT
XLO
XLO
Q4 25
-53.4%
-86.5%
Q3 25
-49.0%
-10.1%
Q2 25
-23.9%
-177.7%
Q1 25
-48.1%
-472.7%
Q4 24
-51.8%
Q3 24
-40.3%
Q2 24
-9.4%
Q1 24
-12.6%
Net Margin
DRCT
DRCT
XLO
XLO
Q4 25
-138.7%
75.7%
Q3 25
-33.6%
-85.4%
Q2 25
-22.2%
-196.0%
Q1 25
-28.9%
-452.7%
Q4 24
-24.0%
Q3 24
-29.6%
Q2 24
-2.7%
Q1 24
-3.5%
EPS (diluted)
DRCT
DRCT
XLO
XLO
Q4 25
$-74.97
$-3.74
Q3 25
$-0.24
$-0.11
Q2 25
$-0.23
$-0.16
Q1 25
$-0.35
$-0.18
Q4 24
$-90.17
Q3 24
$-0.71
Q2 24
$-0.16
Q1 24
$-0.22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DRCT
DRCT
XLO
XLO
Cash + ST InvestmentsLiquidity on hand
$728.0K
$137.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$-7.0M
$35.3M
Total Assets
$20.2M
$154.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DRCT
DRCT
XLO
XLO
Q4 25
$728.0K
$137.5M
Q3 25
$871.0K
$103.8M
Q2 25
$1.6M
$121.6M
Q1 25
$1.8M
$89.1M
Q4 24
$1.4M
Q3 24
$4.1M
Q2 24
$1.1M
Q1 24
$3.3M
Total Debt
DRCT
DRCT
XLO
XLO
Q4 25
Q3 25
$10.8M
Q2 25
$33.5M
Q1 25
$32.9M
Q4 24
Q3 24
$150.0K
Q2 24
$34.8M
Q1 24
$32.4M
Stockholders' Equity
DRCT
DRCT
XLO
XLO
Q4 25
$-7.0M
$35.3M
Q3 25
$-6.7M
$-8.1M
Q2 25
$-24.6M
$7.1M
Q1 25
$-23.3M
$10.7M
Q4 24
$-19.7M
Q3 24
$-16.7M
Q2 24
$-10.5M
Q1 24
$-7.5M
Total Assets
DRCT
DRCT
XLO
XLO
Q4 25
$20.2M
$154.7M
Q3 25
$22.5M
$133.7M
Q2 25
$23.3M
$133.8M
Q1 25
$23.8M
$103.7M
Q4 24
$26.0M
Q3 24
$31.3M
Q2 24
$48.5M
Q1 24
$52.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DRCT
DRCT
XLO
XLO
Operating Cash FlowLast quarter
$-1.9M
$-2.0M
Free Cash FlowOCF − Capex
$-2.1M
FCF MarginFCF / Revenue
-15.3%
Capex IntensityCapex / Revenue
0.7%
Cash ConversionOCF / Net Profit
-0.19×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DRCT
DRCT
XLO
XLO
Q4 25
$-1.9M
$-2.0M
Q3 25
$-1.6M
$-17.5M
Q2 25
$-2.7M
$-14.5M
Q1 25
$-2.7M
$29.0M
Q4 24
$-1.6M
Q3 24
$3.0M
Q2 24
$-4.4M
Q1 24
$-5.7M
Free Cash Flow
DRCT
DRCT
XLO
XLO
Q4 25
$-2.1M
Q3 25
Q2 25
$-14.9M
Q1 25
$29.0M
Q4 24
Q3 24
Q2 24
Q1 24
FCF Margin
DRCT
DRCT
XLO
XLO
Q4 25
-15.3%
Q3 25
Q2 25
-184.0%
Q1 25
988.3%
Q4 24
Q3 24
Q2 24
Q1 24
Capex Intensity
DRCT
DRCT
XLO
XLO
Q4 25
0.7%
Q3 25
0.0%
Q2 25
5.0%
Q1 25
0.8%
Q4 24
Q3 24
Q2 24
Q1 24
Cash Conversion
DRCT
DRCT
XLO
XLO
Q4 25
-0.19×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DRCT
DRCT

Buy Side Advertising$8.2M98%
Other$183.0K2%

XLO
XLO

Segment breakdown not available.

Related Comparisons